["The Lantus Case": What is the benefit of health economics?].
Schöffski
Oliver
O
Gesundheitsmanagement, Friedrich-Alexander-Universität Erlangen-Nürnberg, Nürnberg. oliver.schoeffski@wiso.uni-erlangen.de
D003362:Cost-Benefit Analysis; D003695:Delivery of Health Care / Q000191:economics*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000191:economics*; D005858:Germany; D017048:Health Care Costs; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting; D004364:Pharmaceutical Preparations / Q000191:economics*
D007004:Hypoglycemic Agents; D007328:Insulin; D049528:Insulin, Long-Acting; D004364:Pharmaceutical Preparations; D000069036:Insulin Glargine